Page 2 - Zydus Lifesciences

Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz

The growth was driven by strong performances in the company's domestic and international formulations segments, even as its consumer wellness and US businesses saw muted growth

Zydus Lifesciences Q1 results: Profit up 3% at ₹1466.8 cr, revenue rises 6%

Revenue from operations climbed 5.9 per cent Y-o-Y to ₹6,573.7 crore in Q1 FY26 from ₹6,207.5 crore a year earlier on the back of new drug launches in the US

Zydus gets USFDA approval for a high blood pressure to treat angina

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug used to treat angina and high blood pressure. The company has received final approval from the US Food and Drug Administration (USFDA) for Diltiazem Hydrochloride tablets in strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the drug maker said in a statement. Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle. The company said Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences' Baddi plant in Himachal Pradesh. As per IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of USD 13.9 million in the US.

Zydus Lifesciences up 2% after USFDA nods Diltiazem Hydrochloride tablets

Zydus Lifesciences share price rose 2 per cent, logging an intra-day high at ₹955 per share on BSE after USFDA gave its approval for Diltiazem Hydrochloride Tablets.

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Zydus Lifesciences gets tentative USFDA nod for generic blood cancer drug

Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets. The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement. The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added. The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.

Zydus Lifesciences gets USFDA nod for its painkiller Celecoxib capsules

The company said that the medicine is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain

Stocks to Watch today, July 14: VIP Industries, Adani Green, NCC, DMart

Stocks to Watch today, July 14, 2025: Glenmark Pharma, Avenue Supermarts, RVNL and NCC are some of the top stocks to watch today

Stocks to Watch today, June 19: Jio Financial, Inventurus, Hero MotoCorp

Stocks to Watch today, June 19: Jio Financial, Inventurus Knowledge, Hero MotoCorp, Zydus Lifesciences, Vodafone Idea are among stocks that may buzz in trade

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.

Lower US growth trajectory, margin pressures ahead for Zydus Lifesciences

In the US market, robust growth in the base portfolio, new launches and generic version of Myrbetriq (for overactive bladder) aided its revenue effort in that market

Zydus enters biologics CDMO market with $125 million acquisitions

Zydus Lifesciences will acquire two US biologics manufacturing facilities from Agenus for up to $125 million, gaining immediate manufacturing capabilities and expanding its global presence

Zydus signs deal with Agenus for BOT and BAL cancer therapies in India

Zydus Lifesciences has partnered with Agenus to license the cancer immunotherapies Botensilimab and Balstilimab for India and Sri Lanka, expanding its oncology offerings

Zydus reports 17.6% rise in net profit adjusting for one-off charge

Q4FY25 profit impacted by Rs 219.6 crore goodwill impairment; adjusted profit up 17.6% while US and India businesses report double-digit revenue growth

Zydus Life Q4 profit falls 1% YoY; ₹11 dividend declared; stock down 2%

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter of financial year 2025 (Q4FY25), from ₹1,182 crore in Q4FY24.

Q4 results today: NHPC, Dixon Tech, Hindalco on May 20; see full list

Q4 FY25 company results today: Zydus Lifesciences, Fortis Healthcare, and Torrent Pharma will be among 146 companies to post earnings reports for the January-March quarter

Medicines are just one part of the solution: Zydus' Sharvil Patel

Zydus MD Sharvil Patel says the company is going beyond pharma into med-tech, diagnostics, and rare diseases, aiming for a global footprint while retaining India as the manufacturing hub

USFDA issues 6 observations to Zydus' Gujarat API unit after inspection

Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing. The inspection was conducted from April 21-25, 2025. "The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said. The company is confident of addressing the observations expeditiously, it added.

Zydus Medtech signs deal with Brazil's Braile Biomedica for TAVI technology

To commercialise transcatheter aortic valve system in India, Europe and other select markets

Zydus, Lupin shares fall over US court ruling in Myrbetriq patent case

Companies say they are in process of assessing impact of order on operations